Numerous other HDAC inhibitors have been shown to have anti-myeloma activities, including Sodium Valproate [29], Sodium Butyrate [25], Trichostatin A (TSA) [25], SAHA [30], FR901228 (depsipeptide) [31], LBH589 [32], PXD101 [33], ITF2357 [34], KD5170 [35], tubacin [14], and NVP-LAQ824 [36]. The gene discussed is HDAC9; the disease is plasma cell myeloma.